Top worldwide anti-diabetic products prediction by revenue 2017 and 2024

The data shows the top anti-diabetic products worldwide by revenue in 2017 and a forecast for 2024, in million USD. Novo Nordisk's Ozempic is expected to generate 4.4 billion USD in revenue in 2024. Anti-diabetic medication is commonly ingested orally, with the exception of insulin, exenatide, liraglutide, and pramlintide. Drugs used to treat diabetes mellitus are often called oral hypoglycemic agents or oral antihyperglycemic agents.